Brokers Issue Forecasts for Regeneron Pharmaceuticals, Inc.’s FY2024 Earnings (NASDAQ:REGN)

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) – Stock analysts at Cantor Fitzgerald upped their FY2024 earnings per share (EPS) estimates for Regeneron Pharmaceuticals in a report released on Monday, July 22nd. Cantor Fitzgerald analyst O. Brayer now expects that the biopharmaceutical company will post earnings of $35.16 per share for the year, up from their prior forecast of $34.90. Cantor Fitzgerald currently has a “Neutral” rating and a $1,000.00 target price on the stock. The consensus estimate for Regeneron Pharmaceuticals’ current full-year earnings is $37.02 per share.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $7.97 EPS for the quarter, missing analysts’ consensus estimates of $8.46 by ($0.49). The business had revenue of $3.15 billion during the quarter, compared to analysts’ expectations of $3.19 billion. Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%.

REGN has been the subject of a number of other research reports. Evercore ISI started coverage on Regeneron Pharmaceuticals in a research report on Tuesday, May 14th. They set an “outperform” rating and a $1,150.00 price target for the company. JPMorgan Chase & Co. boosted their price objective on Regeneron Pharmaceuticals from $1,050.00 to $1,150.00 and gave the stock an “overweight” rating in a research note on Monday, June 17th. Canaccord Genuity Group restated a “buy” rating and set a $1,152.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Thursday, June 27th. StockNews.com cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, April 30th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $1,229.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Monday, June 24th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,074.95.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN opened at $1,064.19 on Wednesday. The company has a market cap of $117.26 billion, a P/E ratio of 31.44, a P/E/G ratio of 2.19 and a beta of 0.13. The company has a quick ratio of 4.51, a current ratio of 5.27 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals has a 52 week low of $723.56 and a 52 week high of $1,106.16. The business has a fifty day simple moving average of $1,031.92 and a 200-day simple moving average of $975.57.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $1,059.24, for a total transaction of $105,924.00. Following the sale, the director now owns 17,882 shares in the company, valued at $18,941,329.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, CEO Leonard S. Schleifer sold 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $979.25, for a total transaction of $24,481,250.00. Following the completion of the transaction, the chief executive officer now directly owns 408,200 shares of the company’s stock, valued at $399,729,850. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $1,059.24, for a total value of $105,924.00. Following the transaction, the director now directly owns 17,882 shares of the company’s stock, valued at $18,941,329.68. The disclosure for this sale can be found here. Insiders have sold 65,074 shares of company stock worth $64,546,123 over the last quarter. 7.48% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Several institutional investors have recently made changes to their positions in REGN. HB Wealth Management LLC grew its holdings in Regeneron Pharmaceuticals by 23.4% in the 4th quarter. HB Wealth Management LLC now owns 1,119 shares of the biopharmaceutical company’s stock worth $983,000 after buying an additional 212 shares in the last quarter. Raymond James & Associates grew its holdings in Regeneron Pharmaceuticals by 8.9% in the 4th quarter. Raymond James & Associates now owns 66,999 shares of the biopharmaceutical company’s stock worth $58,845,000 after buying an additional 5,499 shares in the last quarter. CVA Family Office LLC bought a new position in Regeneron Pharmaceuticals in the 4th quarter worth approximately $120,000. Raymond James Financial Services Advisors Inc. grew its holdings in Regeneron Pharmaceuticals by 4.5% in the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 8,772 shares of the biopharmaceutical company’s stock worth $7,704,000 after buying an additional 381 shares in the last quarter. Finally, Portside Wealth Group LLC grew its holdings in Regeneron Pharmaceuticals by 11.9% in the 4th quarter. Portside Wealth Group LLC now owns 546 shares of the biopharmaceutical company’s stock worth $480,000 after buying an additional 58 shares in the last quarter. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.